Risk of Prostate Cancer and Cyclin D1 A870G polymorphism; a Study of Correlation
- *Corresponding Author:
- Rita Singh Majumdhar
Department of Biotechnology
Sharda University, Greater Noida, India
E-mail: [email protected]
Received date: April 19, 2017; Accepted date: May 14, 2017; Published date: May 19, 2017
Citation: Hussain F, Hamid A, Majumdhar RS (2017) Risk of Prostate Cancer and Cyclin D1 A870G polymorphism; a Study of Correlation. J Carcinog Mutagen 8:293. doi: 10.4172/2157-2518.1000293
Copyright: © 2017 Hussain F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cyclin D1 (CCND1) is a critical gene in regulating the progression of cell cycle from G1 to S phases. Like other cyclins, cyclin D1 is frequently dysregulated in multiple cancers. Various clinical and epidemiological studies have suggested the possible association of cyclin D1 A870G polymorphism with the development of various cancers. Hence, we investigated the role of cyclin D1 A870G polymorphism in modulating the risk of prostate cancer (CaP) in a Kashmiri population. We examined a case–control study in which 129 CaP cases were studied for cyclin D1 A870G polymorphism against 221 controls taken from the general population by employing the polymerase chain reaction–restriction length fragment polymorphism technique. We observed the cyclin D1 A allele was more frequently present in the CaP group than the control group. Furthermore, men with AA genotype have an increased risk for developing CaP as compared to the control groups. We found AA genotype statistically significantly associated with dwelling, lymph node metastases, histopathological grade, and PSA levels. Therefore, our findings suggest that A870G polymorphism is a risk factor for CaP development. Furthermore, men with AA genotype have an increased risk of developing CaP.